The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Chardan Capital: Maintaining a "buy" rating on SAB Biotherapeutics ( SAB Biotherapeutics Inc Ordinary Shares(SABS.US) ), raising its price target from $14 to $16.

Northland Capital Markets: Maintaining Applied Digital's ( Applied Digital(APLD.US) ) rating at "Outperforming the Market," while raising the price target from $56 to $82.

RBC Capital: Maintaining Edgewise Therapeutics ( Edgewise Therapeutics, Inc.(EWTX.US) ) rating at "Outperform Market", while raising the price target from $48 to $59.

Needham: Initial rating for NeoVolta ( NeoVolta Inc(NEOV.US) ) stock at "Buy", with a target price of $8.

Oppenheimer: Maintaining an "outperform" rating for Corbus Pharmaceuticals Holdings ( Corbus Pharmaceuticals Holdings Inc(CRBP.US) ), while lowering the price target from $54 to $52.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
SAB Biotherapeutics Inc Ordinary Shares(SABS.US)	to lift	$16.0	$3.86	314.51%	Chardan Capital
Applied Digital(APLD.US)	to lift	$82.0	$45.57	79.94%	Northland Capital Markets
Edgewise Therapeutics, Inc.(EWTX.US)	to lift	$59.0	$34.82	69.44%	RBC Capital
Ionis Pharmaceuticals, Inc.(IONS.US)	to lift	$122.0	$74.31	64.18%	Leerink Partners
Service Properties Trust(SVC.US)	to lift	$2.5	$1.6	56.25%	B. Riley Securities
NeoVolta Inc(NEOV.US)	Initial classification	$8.0	$2.12	277.36%	Needham
Corbus Pharmaceuticals Holdings Inc(CRBP.US)	cut	$52.0	$8.05	545.96%	Oppenheimer
Oxbridge Re Holdings Limited(OXBR.US)	cut	$3.0	$1.03	191.26%	Maxim Group
Nyxoah SA(NYXH.US)	cut	$3.0	$1.59	88.68%	Stifel
Central Garden & Pet Company Class A(CENTA.US)	cut	$53.0	$36.95	43.44%	Canaccord Genuity

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Bernstein: Maintaining its "outperform" rating for Delta Air Lines Delta Air Lines, Inc.(DAL.US) , while raising its price target from $88 to $93.

Citigroup: Maintaining a "buy" rating on Datadog ( Datadog(DDOG.US) ) stock, while raising the price target from $218 to $270.

Argus Research: Maintaining a "buy" rating on Robinhood Markets Robinhood(HOOD.US) stock, while raising the price target from $90 to $110.

Citigroup: Maintaining a "buy" rating on Lam Lam Research Corporation(LRCX.US) ) stock, while raising its price target from $315 to $450.

Deutsche Bank: Maintaining a "buy" rating on Micron Technology Micron Technology, Inc.(MU.US) stock, while raising its price target from $1,000 to $1,500.

Citigroup: Maintaining a "buy" rating on Micron Technology Micron Technology, Inc.(MU.US) , while raising its price target from $840 to $1200.

First Coverage

Bernstein: Initial rating for Bloom Energy ( BLOOM ENERGY CORP(BE.US) ) at "Market Match", with a target price of $276.

Bernstein: Initial rating for GE Vernova ( GE Vernova Inc.(GEV.US) ) at "outperforms the market", with a price target of $1206.

Bernstein: Initial rating for New Era Energy ( NextEra Energy, Inc.(NEE.US) ) at "outperform," with a price target of $107

reduction

Scotiabank: Maintaining Gildan Activewear ( Gildan Activewear Inc.(GIL.US) ) rating at "Outperform Market", while lowering the price target from $72 to $65.

Morgan Stanley: Downgraded ResMed ( ResMed Inc.(RMD.US) ) stock to "market-weighted", with a price target cut from $286 to $230.

UBS: Maintaining a "buy" rating on Constellation Brands ( Constellation Brands, Inc. Class A(STZ.US) ), while lowering the price target from $186 to $175.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.